Trials / Completed
CompletedNCT02319746
COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Basque Health Service · Other Government
- Sex
- All
- Age
- 15 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
General objective: To assess the effectiveness of a treatment program specific for cannabis abuse (cognitive behavioral treatment + pharmacological treatment) compared to standard treatment (pharmacological treatment + psychoeducation) in patients with first episodes psychosis (FEP) cannabis users. Design A multicenter single-blind randomized study with 1 year of follow-up. The effectiveness of a treatment program specific for cannabis abuse (cognitive behavioral treatment + pharmacological treatment) compared to standard treatment (pharmacological treatment + psychoeducation) in patients with first episodes psychosis (FEP) cannabis users will be assessed. Patients will be randomly assigned to one of two treatments: 1. Experimental group (N=50): Cognitive-behavioral treatment specific for cannabis abuse + pharmacological treatment 2. Control group (N=50): standard treatment: psychoeducation + pharmacological treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse | The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention. |
| BEHAVIORAL | Psychoeducation | The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing. |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2018-09-01
- Completion
- 2019-09-01
- First posted
- 2014-12-18
- Last updated
- 2020-01-18
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02319746. Inclusion in this directory is not an endorsement.